Literature DB >> 17491708

Assessment of insulin sensitivity in adults with permanent neonatal diabetes mellitus due to mutations in the KCNJ11 gene encoding Kir6.2.

Jan Skupien1, Maciej T Malecki, Wojciech Mlynarski, Tomasz Klupa, Krzysztof Wanic, Agnieszka Gach, Iwona Solecka, Jacek Sieradzki.   

Abstract

Activating mutations in the KCNJ11 gene encoding the Kir6.2 subunit of ATP-sensitive potassium channel have been described in patients with permanent neonatal diabetes mellitus (PNDM). The main pathophysiological feature of PNDM associated with Kir6.2 mutations is a profound defect in insulin secretion. However, the expression of Kir6.2 protein is not limited to beta-cells; it also includes skeletal muscles, heart, brain, and peripheral nerves. Thus, the hypothesis that Kir6.2 mutations may influence insulin sensitivity in humans seems justified. Moreover, this notion is additionally supported by an animal model of Kir6.2 knock-out mice. Four adult carriers of a Kir6.2 mutation from the Polish population (mean age 31.5 years, range 20-50) were available for this study that aimed to evaluate their insulin sensitivity by the hyperinsulinemic euglycemic clamp technique. Three subjects carried the R201H mutation and one patient was a carrier of the K170N mutation. In addition, eight healthy volunteers with normal glucose tolerance were examined for comparison (mean age 31.0 years, range 20-41). The mean M value, i.e. the amount of metabolized glucose, for PNDM cases equaled 4.49 mg/(kg x min) (range 2.76-6.66) and was significantly lower than in the control group (9.64 mg/(kg x min), range 4.59-18.00). This observation suggests that impaired insulin sensitivity, in addition to profoundly decreased insulin secretion, contributes to the clinical picture of PNDM resulting from mutations in the Kir6.2 gene. An additional factor that might influence insulin sensitivity in our diabetes patients is glucose toxicity that may have appeared due to poor metabolic control prior to the examination (mean HbA1c = 8.95%). The intriguing question to be answered in the future is whether an improvement in insulin action could be seen following the transfer of Kir6.2 mutation carriers to sulphonylurea compounds.

Entities:  

Year:  2006        PMID: 17491708      PMCID: PMC1783575          DOI: 10.1900/RDS.2006.3.17

Source DB:  PubMed          Journal:  Rev Diabet Stud        ISSN: 1613-6071


  12 in total

1.  ATP-sensitive potassium channels participate in glucose uptake in skeletal muscle and adipose tissue.

Authors:  Takashi Miki; Kohtaro Minami; Li Zhang; Mizuo Morita; Tohru Gonoi; Tetsuya Shiuchi; Yasuhiko Minokoshi; Jean-Marc Renaud; Susumu Seino
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-08-13       Impact factor: 4.310

2.  Development and testing of a simple algorithm for a glucose clamp.

Authors:  S M Furler; G S Zelenka; E W Kraegen
Journal:  Med Biol Eng Comput       Date:  1986-07       Impact factor: 2.602

3.  Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients.

Authors:  T Linn; K Ortac; H Laube; K Federlin
Journal:  Metabolism       Date:  1996-12       Impact factor: 8.694

4.  The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation.

Authors:  T Klupa; E L Edghill; J Nazim; J Sieradzki; S Ellard; A T Hattersley; M T Malecki
Journal:  Diabetologia       Date:  2005-04-19       Impact factor: 10.122

Review 5.  Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy.

Authors:  Andrew T Hattersley; Frances M Ashcroft
Journal:  Diabetes       Date:  2005-09       Impact factor: 9.461

6.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.

Authors:  Anna L Gloyn; Ewan R Pearson; Jennifer F Antcliff; Peter Proks; G Jan Bruining; Annabelle S Slingerland; Neville Howard; Shubha Srinivasan; José M C L Silva; Janne Molnes; Emma L Edghill; Timothy M Frayling; I Karen Temple; Deborah Mackay; Julian P H Shield; Zdenek Sumnik; Adrian van Rhijn; Jerry K H Wales; Penelope Clark; Shaun Gorman; Javier Aisenberg; Sian Ellard; Pål R Njølstad; Frances M Ashcroft; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  Reversal of insulin resistance in type I diabetes after treatment with continuous subcutaneous insulin infusion.

Authors:  I Lager; P Lönnroth; H von Schenck; U Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-03

8.  Insulin action is normalized in newly diagnosed type I diabetic patients after three months of insulin treatment.

Authors:  H G Nijs; J K Radder; M Frölich; H M Krans
Journal:  Metabolism       Date:  1988-05       Impact factor: 8.694

Review 9.  Evaluation of insulin sensitivity in clinical practice and in research settings.

Authors:  Lais U Monzillo; Osama Hamdy
Journal:  Nutr Rev       Date:  2003-12       Impact factor: 7.110

10.  Insulin-mediated glucose disposal in type I diabetes: evidence for insulin resistance.

Authors:  S Del Prato; R Nosadini; A Tiengo; P Tessari; A Avogaro; R Trevisan; A Valerio; M Muggeo; C Cobelli; G Toffolo
Journal:  J Clin Endocrinol Metab       Date:  1983-11       Impact factor: 5.958

View more
  4 in total

1.  The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.

Authors:  Joseph C Koster; Francesco Cadario; Cinzia Peruzzi; Carlo Colombo; Colin G Nichols; Fabrizio Barbetti
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

Review 2.  Neonatal diabetes mellitus.

Authors:  Lydia Aguilar-Bryan; Joseph Bryan
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

3.  Phenotype variability and neonatal diabetes in a large family with heterozygous mutation of the glucokinase gene.

Authors:  Maciej Borowiec; Malgorzata Mysliwiec; Wojciech Fendler; Karolina Antosik; Agnieszka Brandt; Maciej Malecki; Wojciech Mlynarski
Journal:  Acta Diabetol       Date:  2011-03-25       Impact factor: 4.280

4.  The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes.

Authors:  Veronica Lang; Peter E Light
Journal:  Pharmgenomics Pers Med       Date:  2010-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.